Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026 - Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) Posts Quarterly Earnings Results

Gilead Sciences (NASDAQ:GILD - Get Free Report) released its quarterly earnings data on Thursday. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.During the same quarter in the previous year, the firm posted $2.02 EPS. Gilead Sciences's revenue for the quarter was up 3.0% on a year-over-ye…

Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026 - Gilead Sciences (NASDAQ:GILD)

Gilead Sciences Inc (NASDAQ:GILD) on Thursday reported adjusted earnings of $2.47 per share, beating the consensus of $2.13. GILD is in positive territory. Get the complete picture here The U.S. drug maker reported revenues of $7.77 billion, beating the consensus of $7.45 billion. Product sales decreased 2% to $7.3 billion, primarily driven by lower Veklury (remdesivir) and Cell Therapy sales, partially offset by higher HIV and Livdelzi (selade…

Cell therapy sales dip 11% for Gilead, as HIV franchise drives quarter

Gilead Sciences said that its cell therapy revenue dropped 11% in the third quarter compared with a year ago, citing lower demand for its two CAR-T cell therapies, Yescarta and Tecartus. The light quarter, with ...